Organization
Cancer Immunotherapy Group (CIT), Bellvitge Biomedical Research Institute (IDIBELL) —OncoBell
1 abstract
Abstract
Phase I/II trial of LAVA-1207, a novel bispecific gamma-delta T-cell engager alone, or with low dose IL-2 or pembrolizumab, in metastatic castration resistant prostate cancer (mCRPC).Org: Department of Medical Oncology, Amsterdam UMC, START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Medical Oncology Department, Catalan Institute of Cancer (ICO), Cancer Immunotherapy Group (CIT), Bellvitge Biomedical Research Institute (IDIBELL) —OncoBell, Early Phase Drug Development Program START Madrid-CIOCC, Centro Integral Oncológico Clara Campal,